C.Q. Pharmaceutical Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

C.Q. Pharmaceutical Holding şirketinin toplam hissedar öz sermayesi CN¥15.6B ve toplam borcu CN¥24.0B olup, bu da borç-öz sermaye oranını 154.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥66.6B ve CN¥51.0B dir. C.Q. Pharmaceutical Holding 'in FAVÖK'ü CN¥1.5B faiz karşılama oranı 2.1 dur. Şirketin CN¥6.7B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

154.2%

Borç/özkaynak oranı

CN¥24.04b

Borç

Faiz karşılama oranı	2.1x
Nakit	CN¥6.70b
Eşitlik	CN¥15.58b
Toplam yükümlülükler	CN¥51.02b
Toplam varlıklar	CN¥66.60b

Son finansal sağlık güncellemeleri

Is C.Q. Pharmaceutical Holding (SZSE:000950) Using Too Much Debt?

Jul 13

Does C.Q. Pharmaceutical Holding (SZSE:000950) Have A Healthy Balance Sheet?

Mar 28

Recent updates

C.Q. Pharmaceutical Holding's (SZSE:000950) Returns On Capital Not Reflecting Well On The Business

Nov 12

C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) Doing What It Can To Lift Shares

Oct 25

Is C.Q. Pharmaceutical Holding (SZSE:000950) Using Too Much Debt?

Jul 13

C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) Doing What It Can To Lift Shares

Jun 11

Does C.Q. Pharmaceutical Holding (SZSE:000950) Have A Healthy Balance Sheet?

Mar 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 000950 'nin kısa vadeli varlıkları ( CN¥57.6B ) kısa vadeli yükümlülüklerini ( CN¥44.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 000950 şirketinin kısa vadeli varlıkları ( CN¥57.6B ) uzun vadeli yükümlülüklerini ( CN¥6.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 000950 'nin net borç/öz sermaye oranı ( 111.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 000950 şirketinin borç/öz sermaye oranı son 5 yılda 70% seviyesinden 154.2% seviyesine yükseldi.

Borç Kapsamı: 000950 'nin borcu işletme nakit akışı ( 1.4% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 000950 'in borcuna ilişkin faiz ödemeleri EBIT ( 2.1 x kapsam) tarafından iyi karşılanmıyor.

C.Q. Pharmaceutical Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is C.Q. Pharmaceutical Holding (SZSE:000950) Using Too Much Debt?

Does C.Q. Pharmaceutical Holding (SZSE:000950) Have A Healthy Balance Sheet?

Recent updates

C.Q. Pharmaceutical Holding's (SZSE:000950) Returns On Capital Not Reflecting Well On The Business

C.Q. Pharmaceutical Holding Co., Ltd. Proposes Third Quarter Dividend for the Third Quarter of 2024

C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) Doing What It Can To Lift Shares

Third quarter 2024 earnings released: EPS: CN¥0.031 (vs CN¥0.002 in 3Q 2023)

C.Q. Pharmaceutical Holding Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 23%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.18 in 2Q 2023)

Is C.Q. Pharmaceutical Holding (SZSE:000950) Using Too Much Debt?

C.Q. Pharmaceutical Holding Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024

C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) Doing What It Can To Lift Shares

C.Q. Pharmaceutical Holding Co., Ltd. Implements Final Cash Dividend of A Shares for 2023, Payable on 6 June 2024

C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 17, 2024

C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.10 in 1Q 2023)

C.Q. Pharmaceutical Holding Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does C.Q. Pharmaceutical Holding (SZSE:000950) Have A Healthy Balance Sheet?

C.Q. Pharmaceutical Holding Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

C.Q. Pharmaceutical Holding Co., Ltd. Announces Executive Appointments

Third quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.16 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.18 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

New minor risk - Dividend sustainability

C.Q. Pharmaceutical Holding Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 11 July 2023

High number of new directors

C.Q. Pharmaceutical Holding Co., Ltd. Approves Cash Dividend for 2022

First quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.06 in 1Q 2022)

Investor sentiment improves as stock rises 21%

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 2Q 2021)

High number of new directors

Investor sentiment improved over the past week

C.Q. Pharmaceutical Holding Co., Ltd. Announces Implementation of 2021 Final Profit Distribution Plan, Payable on 28 June 2022

C.Q. Pharmaceutical Holding Co., Ltd. Announces Cash Dividend for 2021

C.Q. Pharmaceutical Holding Co., Ltd. Proposes Dividend for 2021

C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.05 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.18 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.05 in 1Q 2020)

C.Q. Pharmaceutical Holding Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥4.98

New 90-day low: CN¥5.12

Third quarter earnings released

Earnings released

First half earnings released

C.Q. Pharmaceutical Holding Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥5.71

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin